| Q42177637 | A tetrahedral transition state at the active sites of the 20S proteasome is coupled to opening of the alpha-ring channel |
| Q37607995 | AFM of biological complexes: what can we learn? |
| Q90098730 | Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D |
| Q37386064 | Atomic force microscopy as a tool to study the proteasome assemblies. |
| Q36308388 | Atomic force microscopy of the proteasome. |
| Q90218719 | Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action |
| Q36308392 | Characterization of noncompetitive regulators of proteasome activity |
| Q51743465 | Comparison of neuroprotective efficacy of poly-arginine R18 and R18D (D-enantiomer) peptides following permanent middle cerebral artery occlusion in the Wistar rat and in vitro toxicity studies. |
| Q41940143 | Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon |
| Q26825417 | DangER: protein ovERload. Targeting protein degradation to treat myeloma |
| Q38828129 | Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways. |
| Q39194017 | Dissecting a role of a charge and conformation of Tat2 peptide in allosteric regulation of 20S proteasome. |
| Q33588424 | Effect of noncompetitive proteasome inhibition on bortezomib resistance |
| Q47137426 | Electrostatic Map Of Proteasome α-Rings Encodes The Design of Allosteric Porphyrin-Based Inhibitors Able To Affect 20S Conformation By Cooperative Binding. |
| Q39602920 | Fundamental reaction pathway and free energy profile for inhibition of proteasome by Epoxomicin |
| Q35756052 | Fundamental reaction pathway and free energy profile of proteasome inhibition by syringolin A (SylA). |
| Q37365069 | Fundamental reaction pathway for peptide metabolism by proteasome: insights from first-principles quantum mechanical/molecular mechanical free energy calculations |
| Q38177328 | Harnessing proteasome dynamics and allostery in drug design. |
| Q36381253 | Highbrow proteasome in high-throughput technology |
| Q35107386 | Inhibition of human and yeast 20S proteasome by analogues of trypsin inhibitor SFTI-1 |
| Q35843506 | Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat Protein |
| Q43192247 | Molecular basis for proline- and arginine-rich peptide inhibition of proteasome |
| Q36691554 | Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo |
| Q38766823 | Noncovalent inhibitors of human 20S and 26S proteasome based on trypsin inhibitor SFTI-1. |
| Q118469336 | Nostocyclopeptides as New Inhibitors of 20S Proteasome |
| Q37878771 | Novel proteasome inhibitors to overcome bortezomib resistance |
| Q42019078 | Optimal length transportation hypothesis to model proteasome product size distribution |
| Q37765860 | Oxidative protein damage and the proteasome. |
| Q42351442 | Pathophysiology and Neuroprotective Strategies in Hypoxic-Ischemic Brain Injury and Stroke |
| Q39008879 | Peptide Pharmacological Approaches to Treating Traumatic Brain Injury: a Case for Arginine-Rich Peptides |
| Q37262591 | Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells |
| Q57929840 | Perinatal Hypoxic-Ischemic Encephalopathy and Neuroprotective Peptide Therapies: A Case for Cationic Arginine-Rich Peptides (CARPs) |
| Q50094040 | Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat. |
| Q40942447 | Potential allosteric modulators of the proteasome activity. |
| Q93210381 | Proline- and Arginine-Rich Peptides as Flexible Allosteric Modulators of Human Proteasome Activity |
| Q36332904 | Proline-mediated proteasomal degradation of the prostate-specific tumor suppressor NKX3.1. |
| Q38241687 | Proline-rich antimicrobial peptides: potential therapeutics against antibiotic-resistant bacteria |
| Q44614547 | Promoting proteasomes: trash to treasure |
| Q92157489 | Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders |
| Q33554490 | Proteasome inhibitors and cardiac cell growth |
| Q37979388 | Proteasome inhibitors: an expanding army attacking a unique target |
| Q36275413 | Proteasome-associated proteins: regulation of a proteolytic machine |
| Q40174425 | Protection against myocardial ischemia-reperfusion injury by the angiogenic Masterswitch protein PR 39 gene therapy: the roles of HIF1alpha stabilization and FGFR1 signaling |
| Q91663542 | Pyrazolones Activate the Proteasome by Gating Mechanisms and Protect Neuronal Cells from β-Amyloid Toxicity |
| Q27000202 | Regulation of the proteasome by ATP: implications for ischemic myocardial injury and donor heart preservation |
| Q33974768 | Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing |
| Q33307877 | Role of proteasomes in disease |
| Q42989557 | Structure-function analysis of tritrpticin analogs: potential relationships between antimicrobial activities, model membrane interactions, and their micelle-bound NMR structures |
| Q38246060 | The future of proteasome inhibitors in relapsed/refractory multiple myeloma. |
| Q36721779 | The role of allostery in the ubiquitin-proteasome system |
| Q37103852 | The therapeutic potential of the proteasome in leukaemia |
| Q28305844 | The ubiquitin-proteasome system |
| Q41062674 | Two-substrate association with the 20S proteasome at single-molecule level |